Page 1/27 NRF2 signaling is repressed in HPV-driven head and neck cancer and correlates with better prognosis: HPV-E6/E7 confers chemosensitivity by inhibiting NRF2 Pushkal Sinduvadi Ramesh Centre for Excellence in Molecular Biology and Regenerative Medicine, Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education, Mysuru Venugopal Reddy Bovilla Centre for Excellence in Molecular Biology and Regenerative Medicine, Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education, Mysuru Vikas Swamy School of Life Sciences, JSS Academy of Higher Education & Research, Mysuru Nandini Nandish Manoli JSS Medical College, JSS Academy of Higher Education & Research Krishnappa Dasegowda Radha Maternity and ENT clinic, Mandya Siddegowda Siddegowda Mandya Institute of Medical Sciences Shilpa Chandrashekarappa JSS Medical College, JSS Academy of Higher Education & Research Vishveshwara Somasundara Bharath Hospital & Institute of Oncology Devanand Devegowda Centre for Excellence in Molecular Biology and Regenerative Medicine, Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education, Mysuru Rajesh Thimmulappa (  rakeshkt@jssuni.edu.in ) Centre for Excellence in Molecular Biology and Regenerative Medicine, Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education, Mysuru Research Article Keywords: HPV, HNSCC, NRF2, p16, NQO1, p53, prognosis, Treatment de-escalation Posted Date: April 5th, 2022